Fabhalta® (iptacopan)
for Paroxysmal Nocturnal Hemoglobinuria
Fabhalta (iptacopan) is approved to treat adults with paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN) with a urine protein-to-creatinine ratio (UPCR) of ≥ 1.5 g/g, and complement 3 glomerulopathy (C3G) to reduce proteinuria. Fabhalta works by blocking complement factor B, which prevents red blood cell destruction, anemia, and proteinuria, and reduces kidney damage. Continued approval may depend on clinical trial outcomes.
